PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis
Post-transplant Cyclophosphamide and Urinary-derived Human Chorionic Gonadotropin and Epidermal Growth Factor (uhCG/EGF) as Graft Versus Host Disease Prophylaxis for Mismatched Unrelated Donor Transplantation
Henry Ford Health System
18 participants
Dec 23, 2021
INTERVENTIONAL
Conditions
Summary
So this a Phase I study with primary objective to determine the feasibility and safety of combining post-transplant cyclophosphamide and urinary-derived human chorionic gonadotropin and epidermal growth factor (uhCG/EGF) as graft versus host disease prophylaxis in stem cell transplant with MMUDs Secondary objectives are to determine the incidence acute and chronic GVHD, progression-free survival , and overall survival
Eligibility
Inclusion Criteria8
- Patients with hematologic malignancy who have the indication for Allogeneic SCT and have no MRD or MUD.
- Age 18-70 years old
- Performance score of at least 80% by Karnofsky
- Adequate kidney and liver function as demonstrated by:
- Creatinine clearance should be >60 ml/min
- Total Bilirubin <1.5, ALT/AST/Alk Phos < 2.5 x normal. No evidence of chronic active hepatitis or cirrhosis.
- Negative Beta HCG test in a woman with childbearing potential, defined as not post-menopausal for 12 months or no previous surgical sterilization. Women of childbearing potential must be willing to use an effective contraceptive measure while on study.
- Patient or patient's legal representative, parent(s) or guardian able to sign informed consent.
Exclusion Criteria12
- Positive for HIV, HBsAg, HCV or other viral hepatitis or cirrhosis from any cause
- Active or prior CNS leukemia, unless in complete remission for at least 2 months.
- History of serious chronic mental disorder or drug-abuse accompanied by documented problems of compliance with therapeutic programs.
- Uncontrolled infection
- Donor specific antibodies
- Ejection fraction <40% or history of heart failure or cardiovascular disease
- history thrombosis or current thrombosis, family history of thrombosis, severe obesity, or thrombophilia.
- Previous history hormone responsive cancer
- history of seizure
- history of migraine or severe headache
- history of asthma
- history of uterine fibroid
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
PTCY for 2 doses on day +3 and +4 after stem cell transplant followed by uhCG/EGF subcutaneously on day +7, +9 and +11 post stem cell transplant
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04886726